lebrikizumab
lebrikizumab: sourced relationships with 1 company · 8 clinical trials tracked.
lebrikizumab evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
How could lebrikizumab → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ELI LILLY & Co (LLY) Atopic Dermatitis; Atopic Hand and Foot Dermatitis | Phase 4 |
Clinical Trial Registry Records (8)
A Phase 4, Prospective, Multicenter, Single-Arm, Pragmatic Interventional Cohort Study Evaluating Real-World Outcomes and Dosing Patterns of Ebglyss (Lebrikizumab) in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Primary endpoint: Proportion of participants achieving an Investigator's Global Assessment (IGA) score of 0 or 1
Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients: A 24-Week Study
Primary endpoint: Percent change from baseline in weekly average Peak Pruritus Numeric Rating Scale (PP-NRS) at week 24
A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden
Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% Reduction from Baseline in EASI), or a ≥4-point Reduction in Pruritus Numerical Rating Scale (NRS) from Baseline
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Primary endpoint: Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline
A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Primary endpoint: Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)
An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index 75 (≥75% Reduction From Baseline in EASI) at Week 16
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI-75) at Week 16
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Primary endpoint: Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from Baseline
Frequently asked questions
Which companies have sourced relationships with lebrikizumab?
lebrikizumab has dated SEC/FDA relationship records for ELI LILLY & Co.
How many clinical trials involve lebrikizumab?
BioSniper tracks 8 clinical trials involving lebrikizumab.